questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Interférons
Interféron de type I
Interféron alpha
Interféron alpha-2
Interféron alpha-2 : Questions médicales fréquentes
Diagnostic
5
Infections virales
Diagnostic médical
Tests de laboratoire
Marqueurs tumoraux
Hépatite C
Symptômes cliniques
Effets secondaires
Évaluation clinique
Critères de traitement
Maladies infectieuses
Symptômes
5
Effets indésirables
Symptômes
Dépression
Troubles de l'humeur
Système immunitaire
Immunomodulation
Réaction allergique
Symptômes cutanés
Symptômes gastro-intestinaux
Effets indésirables
Prévention
5
Prévention des effets secondaires
Médicaments adjuvants
Mesures préventives
Dépistage
Éducation du patient
Soins médicaux
Prévention des infections
Hygiène
Vaccinations
Prévention des maladies
Traitements
5
Administration de médicaments
Injections
Durée du traitement
Protocoles de traitement
Monothérapie
Thérapies combinées
Objectifs thérapeutiques
Charge virale
Précautions médicales
Surveillance des patients
Complications
5
Complications
Troubles neurologiques
Gestion des complications
Surveillance médicale
Maladies auto-immunes
Exacerbation des symptômes
Signes de complications
Urgences médicales
Fréquence des complications
Surveillance des patients
Facteurs de risque
5
Facteurs de risque
Comorbidités
Antécédents médicaux
Maladies hépatiques
Mode de vie
Efficacité du traitement
Interactions médicamenteuses
Précautions médicales
Facteurs génétiques
Réponse au traitement
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Interféron alpha-2 : Questions médicales les plus fréquentes",
"headline": "Interféron alpha-2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Interféron alpha-2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-02",
"dateModified": "2026-02-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Interféron alpha-2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Interféron alpha",
"url": "https://questionsmedicales.fr/mesh/D016898",
"about": {
"@type": "MedicalCondition",
"name": "Interféron alpha",
"code": {
"@type": "MedicalCode",
"code": "D016898",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.440.890.250"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Interféron alpha-2",
"alternateName": "Interferon alpha-2",
"code": {
"@type": "MedicalCode",
"code": "D000077190",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Valentyn Oksenych",
"url": "https://questionsmedicales.fr/author/Valentyn%20Oksenych",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway."
}
},
{
"@type": "Person",
"name": "Christopher Koh",
"url": "https://questionsmedicales.fr/author/Christopher%20Koh",
"affiliation": {
"@type": "Organization",
"name": "Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Theo Heller",
"url": "https://questionsmedicales.fr/author/Theo%20Heller",
"affiliation": {
"@type": "Organization",
"name": "Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Lin Chen",
"url": "https://questionsmedicales.fr/author/Lin%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China."
}
},
{
"@type": "Person",
"name": "Jia Liu",
"url": "https://questionsmedicales.fr/author/Jia%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37211985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bjh.18845"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacodynamic of Recombinant Human Interferon Alpha-2b Nasal Drops and Effective Prophylaxis Against SARS-COV-2 Infection.",
"datePublished": "2024-04-10",
"url": "https://questionsmedicales.fr/article/38597374",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1089/jir.2023.0193"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adjuvant Topical Interferon Alpha 2b for the Treatment of Monkeypox Ocular Manifestations.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37643461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003360"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis.",
"datePublished": "2024-10-13",
"url": "https://questionsmedicales.fr/article/39396949",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12879-024-10057-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.",
"datePublished": "2023-07-27",
"url": "https://questionsmedicales.fr/article/37501105",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03092-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Interférons",
"item": "https://questionsmedicales.fr/mesh/D007372"
},
{
"@type": "ListItem",
"position": 6,
"name": "Interféron de type I",
"item": "https://questionsmedicales.fr/mesh/D007370"
},
{
"@type": "ListItem",
"position": 7,
"name": "Interféron alpha",
"item": "https://questionsmedicales.fr/mesh/D016898"
},
{
"@type": "ListItem",
"position": 8,
"name": "Interféron alpha-2",
"item": "https://questionsmedicales.fr/mesh/D000077190"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Interféron alpha-2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Interféron alpha-2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Interféron alpha-2",
"description": "Comment diagnostiquer une infection nécessitant l'interféron alpha-2 ?\nQuels tests sont utilisés pour évaluer l'efficacité de l'interféron alpha-2 ?\nQuels symptômes indiquent un besoin d'interféron alpha-2 ?\nComment évaluer les effets secondaires de l'interféron alpha-2 ?\nQuels critères déterminent l'utilisation de l'interféron alpha-2 ?",
"url": "https://questionsmedicales.fr/mesh/D000077190#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Interféron alpha-2",
"description": "Quels sont les effets secondaires courants de l'interféron alpha-2 ?\nL'interféron alpha-2 provoque-t-il des symptômes psychologiques ?\nComment l'interféron alpha-2 affecte-t-il le système immunitaire ?\nQuels symptômes indiquent une réaction allergique à l'interféron alpha-2 ?\nL'interféron alpha-2 peut-il causer des symptômes gastro-intestinaux ?",
"url": "https://questionsmedicales.fr/mesh/D000077190#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Interféron alpha-2",
"description": "Peut-on prévenir les effets secondaires de l'interféron alpha-2 ?\nQuelles mesures préventives sont recommandées avant le traitement ?\nL'éducation du patient est-elle importante avant le traitement ?\nComment minimiser le risque d'infection pendant le traitement ?\nDes vaccinations sont-elles recommandées avant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000077190#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Interféron alpha-2",
"description": "Comment l'interféron alpha-2 est-il administré ?\nQuelle est la durée du traitement par interféron alpha-2 ?\nL'interféron alpha-2 est-il utilisé en monothérapie ?\nQuels sont les objectifs du traitement par interféron alpha-2 ?\nQuelles précautions doivent être prises lors du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000077190#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Interféron alpha-2",
"description": "Quelles sont les complications possibles de l'interféron alpha-2 ?\nComment gérer les complications liées à l'interféron alpha-2 ?\nL'interféron alpha-2 peut-il aggraver des maladies préexistantes ?\nQuels signes indiquent une complication grave ?\nLes complications sont-elles fréquentes avec l'interféron alpha-2 ?",
"url": "https://questionsmedicales.fr/mesh/D000077190#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Interféron alpha-2",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nLes antécédents médicaux influencent-ils le traitement par interféron alpha-2 ?\nLe mode de vie affecte-t-il l'efficacité de l'interféron alpha-2 ?\nY a-t-il des interactions médicamenteuses à considérer ?\nLes facteurs génétiques influencent-ils la réponse au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000077190#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection nécessitant l'interféron alpha-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des tests sanguins, biopsies et évaluation clinique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité de l'interféron alpha-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de charge virale et des marqueurs tumoraux sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'interféron alpha-2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Symptômes de maladies comme l'hépatite C ou certains cancers peuvent justifier son usage."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires de l'interféron alpha-2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des examens cliniques et des questionnaires sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels critères déterminent l'utilisation de l'interféron alpha-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent le type de maladie, la gravité et la réponse aux traitements antérieurs."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de l'interféron alpha-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, fièvre, douleurs musculaires et symptômes pseudo-grippaux sont fréquents."
}
},
{
"@type": "Question",
"name": "L'interféron alpha-2 provoque-t-il des symptômes psychologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut causer dépression, anxiété et troubles de l'humeur chez certains patients."
}
},
{
"@type": "Question",
"name": "Comment l'interféron alpha-2 affecte-t-il le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il stimule le système immunitaire, augmentant la réponse contre les infections et tumeurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réaction allergique à l'interféron alpha-2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éruptions cutanées, démangeaisons, gonflement et difficultés respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'interféron alpha-2 peut-il causer des symptômes gastro-intestinaux ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements et diarrhées sont possibles chez certains patients."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de l'interféron alpha-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments adjuvants peuvent aider à réduire certains effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluation médicale complète et tests de dépistage des infections sont conseillés."
}
},
{
"@type": "Question",
"name": "L'éducation du patient est-elle importante avant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le patient sur les effets, le traitement et les soins est essentiel."
}
},
{
"@type": "Question",
"name": "Comment minimiser le risque d'infection pendant le traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules, pratiquer une bonne hygiène et se faire vacciner si possible."
}
},
{
"@type": "Question",
"name": "Des vaccinations sont-elles recommandées avant le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent être recommandées, selon l'état de santé du patient."
}
},
{
"@type": "Question",
"name": "Comment l'interféron alpha-2 est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement administré par injection sous-cutanée ou intramusculaire."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement par interféron alpha-2 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie selon la maladie, souvent de plusieurs mois à un an."
}
},
{
"@type": "Question",
"name": "L'interféron alpha-2 est-il utilisé en monothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être utilisé seul ou en association avec d'autres médicaments selon le cas."
}
},
{
"@type": "Question",
"name": "Quels sont les objectifs du traitement par interféron alpha-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les objectifs incluent la réduction de la charge virale et l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles précautions doivent être prises lors du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillance régulière des effets secondaires et ajustement de la dose si nécessaire."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'interféron alpha-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Complications incluent des troubles hématologiques, neurologiques et psychiatriques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'interféron alpha-2 ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance étroite et un ajustement du traitement sont nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "L'interféron alpha-2 peut-il aggraver des maladies préexistantes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut exacerber certaines conditions comme les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des saignements, des douleurs thoraciques ou des troubles neurologiques nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec l'interféron alpha-2 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications varient selon les patients, mais une surveillance est toujours recommandée."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Âge avancé, comorbidités et antécédents de troubles psychiatriques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le traitement par interféron alpha-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou psychiatriques peuvent influencer le traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'efficacité de l'interféron alpha-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut améliorer l'efficacité du traitement et réduire les effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des interactions médicamenteuses à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interagir avec l'interféron alpha-2, nécessitant une attention particulière."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques influencent-ils la réponse au traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent affecter la réponse et la tolérance au traitement."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/02/2026
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Cancer Hospital Affiliated to Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Institute for Physics, University of Freiburg, Germany.
FDM-Freiburg Center for Data Analysis and Modeling, University of Freiburg, Freiburg, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, Leipzig, Germany and Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, Berlin, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, Leipzig, Germany and Department of General-, Visceral- and Transplantation Surgery, Charité University Medicine Berlin, Berlin, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", Division Virus-Associated Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Institute for Physics, University of Freiburg, Germany.
FDM-Freiburg Center for Data Analysis and Modeling, University of Freiburg, Freiburg, Germany.
Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
Department of Gastroenterology, Brighton & Sussex University Hospitals, Brighton, UK.
Publications dans "Interféron alpha-2" :
2 publications dans cette catégorie
Affiliations :
CUBRIC, Cardiff University Brain Research Imaging Centre, Cardiff, UK; Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, Brighton, UK.
Publications dans "Interféron alpha-2" :
1 publication dans cette catégorie
Affiliations :
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia. amn25@yandex.ru.
Publications dans "Interféron alpha-2" :
1 publication dans cette catégorie
Affiliations :
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Publications dans "Interféron alpha-2" :
1 publication dans cette catégorie
Affiliations :
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Publications dans "Interféron alpha-2" :
1 publication dans cette catégorie
Affiliations :
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Publications dans "Interféron alpha-2" :
1 publication dans cette catégorie
Affiliations :
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
Publications dans "Interféron alpha-2" :
Neutrophil extracellular traps (NETs) may play a pathogenic role in the thrombosis associated with myeloproliferative neoplasms (MPNs). We measured serum NET levels in 128 pretreatment samples from pa...
The recombinant human interferon alpha-2b (IFN-α2b) nasal drop formulation (Nasalferon) was studied as prophylaxis for SARS-CoV-2. Healthy volunteers between 19 and 80 years of age received 0.5 millio...
The aim of this study was to report a case of ocular Mpox that responded favorably to treatment with topical interferon and oral doxycycline....
This is a case report of a previously healthy 24-year-old woman who developed a pustular rash, headache, fever, arthralgia, sore throat, and asthenia 3 weeks before attending to our clinic. Her main c...
Mpox with ocular manifestations diagnosis was confirmed by real-time quantitative reverse transcription polymerase chain reaction assay (qRT-PCR) testing; samples were taken from corneal, conjunctival...
Alternative and efficacious treatment options for Mpox ocular manifestations are needed to prevent further disease progression and sequelae in countries with no access to the gold-standard therapy. To...
The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was ...
We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022. Logistic regression identified independent factors influencing clinical cure. The predictive a...
A total of 120 patients were enrolled in the final analysis. Among the cohort of patients under study, 71 (59.1%) patients had clinical cure while 49 (40.9%) patients did not. Hepatitis B surface anti...
This study provided predictive formulas for clinical cure, offering valuable insights for CHB treatment. PegIFN and NAs exhibited efficacy. Future research that explores additional factors, such as HB...
Ocular surface squamous neoplasia (OSSN) comprises a wide spectrum of squamous tumors, from which corneal/conjunctival intraepithelial neoplasia (CIN) is the most common one. The classic treatment is ...
Patients diagnosed with localized CIN were evaluated by slit lamp and impression cytology and were randomly given MMC 0.04% or INF2b (1 million IU/mL) 4 times daily until neoplasia resolution. Time of...
Seventeen patients were included. Nine patients were treated with MMC and 8 with IFNα2b. All patients responded to treatment. The resolution time in days was 59.11 ± 24.02 in patients treated with MMC...
Topical chemotherapy with MMC and IFNα2b demonstrate pharmacological safety and efficacy. Therefore, these drugs could be considered as primary therapies for localized CIN ....
Limited data have been reported on achieving functional cure using pegylated interferon (Peg-IFN) alpha-2b treatment for postpartum hepatitis B e antigen (HBeAg)-negative women with chronic hepatitis ...
A total of 150 HBeAg-negative postpartum women were retrospectively recruited.47 patients received Peg-IFN alpha-2b [Peg-IFN(+) group] and 103 patients did not [Peg-IFN(-) group]. Propensity score mat...
At week 48,the HBsAg loss and seroconversion rate in Peg-IFN(+) group were 51.06%(24/47) and 40.43%(19/47), respectively. Even after PSM, Peg-IFN(+) group still showed higher HBsAg loss rate (50.00% v...
Peg-IFN alpha-2b treatment could achieve a high rate of HBsAg loss and seroconversion in HBeAg-negative postpartum women with reliable safety, particularly for patients experience postpartum flare and...
Interferons (IFNs) are universally acknowledged for their pivotal role in antiviral and anticancer responses. Thus, the primary aim of our study was to explore the expressions of IFN-α1b, α2b, and gam...
Type I interferons (IFN-I)-a group of cytokines with immunomodulatory, antiproliferative, and antiviral properties-are widely used as therapeutics for various cancers and viral diseases. Since IFNs ar...
In this study, we developed an attenuated EPEC strain that cannot colonize the host but can secrete functional human IFNα2 variant through the T3SS. We found that this bacteria-secreted IFN exhibited ...
These findings present a potential novel approach for the oral delivery of IFN via secreting bacteria....
Interferons have been identified as a potential treatment alternative for coronavirus disease 2019. This study assessed the safety, tolerability, bioavailability, and biological activity of inhaled in...
A double-blind, randomized, phase I clinical trial was conducted with two cohorts of healthy subjects aged 18-50 years. The first cohort received 2.5 MIU of inhaled IFN-α2b twice daily for 10 days (n ...
Exposure to inhaled IFN-α2b at 2.5-MIU or 5-MIU doses did not produce statistically significant changes in participant vital signs, or elicit new symptoms, and standard hematological and biochemical b...
Inhaled IFN-α2b was preliminarily safe and well tolerated, and induced systemic biological activity in healthy subjects....
The trial was registered in ClinicalTrials.gov (NCT04988217), 3 August, 2021....
Basal cell carcinoma (BCC) is the most common cutaneous cancer. We report the efficacy and aesthetic outcome of intralesional IFN-α 2b injection for the treatment of BCC and compare with the surgical ...
Intralesional IFN-α 2b was injected in 58 BCC lesions from 20 patients three times a week for three weeks. Control group was retrospectively selected among patients who underwent surgical method (stan...
Two patients (four lesions) failed to complete the treatment period. After three weeks, 40 (68.96%) lesions were completely cured. Nine (15.51%) lesions achieved complete healing in less than 9 sessio...
Intralesional IFN-α 2b injection is an appropriate treatment choice for BCC....
We used Iranian registery of Clinical trials; The IRCT code is: 2017093017756N30....